Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Editing02:23

RNA Editing

9.0K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.0K
Neural Regulation01:37

Neural Regulation

39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
CRISPR01:59

CRISPR

51.4K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
51.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A diagnostic plasma omics-biomarker for Alzheimer's disease informed by microglial single-cell transcriptomics: A pilot study.

Alzheimer's & dementia (New York, N. Y.)·2026
Same author

<i>TOMM40</i> '523' genotype induces sex- and tissue- specific differences in cholesterol and triglyceride levels in an <i>APOE-TOMM40</i> humanized mouse model.

bioRxiv : the preprint server for biology·2026
Same author

A diagnostic plasma omics-biomarker for Alzheimer's disease informed by microglial single-cell transcriptomics: A pilot study.

bioRxiv : the preprint server for biology·2026
Same author

[Expression of Concern] ISL1 promotes cancer progression and inhibits cisplatin sensitivity in triple‑negative breast cancer cells.

International journal of molecular medicine·2026
Same author

Quadrupole-Driven Chiral Emission with Dipole-Quadrupole Interference Gating in an Achiral Nanocrescent.

Nano letters·2026
Same author

Cell-specific DNA methylation in human alpha and beta cells regulates gene expression in type 2 diabetes.

Nature metabolism·2026
Same journal

A DNA-guided prokaryotic argonaute enables programmable RNA cleavage for sequencing and quality control of <i>in vitro</i>-transcribed RNAs.

Molecular therapy. Nucleic acids·2026
Same journal

Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the <i>HBG1/2</i> promoters.

Molecular therapy. Nucleic acids·2026
Same journal

Optimizing twin prime editing components for scalable genome editing and therapy in spinocerebellar ataxia type 3.

Molecular therapy. Nucleic acids·2026
Same journal

Enhancing protein expression in humans through codon optimization with transformer and contrastive learning.

Molecular therapy. Nucleic acids·2026
Same journal

Neonatal expression of human FMRP isoform corrects cortical deficits and improves behavior in a mouse model of fragile X syndrome.

Molecular therapy. Nucleic acids·2026
Same journal

Meta-analysis of adverse events in clinical studies with antisense oligonucleotide therapies.

Molecular therapy. Nucleic acids·2026
See all related articles

Related Experiment Video

Updated: Jul 7, 2025

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.6K

Neuronal-type-specific epigenome editing to decrease SNCA expression: Implications for precision medicine in

Zhiguo Sun1, Boris Kantor2, Ornit Chiba-Falek3,4

  • 1CLAIRIgene, LLC, Durham, NC 27701, USA.

Molecular Therapy. Nucleic Acids
|December 22, 2023
PubMed
Summary
This summary is machine-generated.

We developed a novel gene therapy targeting SNCA overexpression in Parkinson's disease (PD) and dementia with Lewy bodies (DLB). This epigenome therapy shows promise for treating synucleinopathies by specifically reducing SNCA in affected neurons.

Keywords:
DLBMT: RNA/DNA editingPDParkinson’s diseaseSNCAalpha-synucleincholinergic neurondementia with Lewy bodiesdopaminergic neuronsepigenetic editinggene therapyhiPSChuman induced pluripotent stem cellslentivirus vectorssynucleinopathies

More Related Videos

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery
07:49

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery

Published on: May 30, 2025

956
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.5K

Related Experiment Videos

Last Updated: Jul 7, 2025

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models
13:47

Lentiviral Vector Platform for the Efficient Delivery of Epigenome-editing Tools into Human Induced Pluripotent Stem Cell-derived Disease Models

Published on: March 29, 2019

9.6K
CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery
07:49

CRISPR Epigenome Editing in Human Cells using Plasmid DNA Transfection and mRNA Nucleofection Delivery

Published on: May 30, 2025

956
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.5K

Area of Science:

  • Neuroscience
  • Genetics
  • Molecular Biology

Background:

  • SNCA gene overexpression is central to synucleinopathies like Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
  • PD and DLB exhibit distinct pathological features despite shared similarities, necessitating targeted therapeutic approaches.
  • Current treatments for synucleinopathies primarily manage symptoms, highlighting the need for disease-modifying therapies.

Purpose of the Study:

  • To engineer a neuronal-type-specific epigenome therapy targeting SNCA for synucleinopathies.
  • To achieve precise downregulation of SNCA in dopaminergic and cholinergic neurons implicated in PD and DLB.
  • To validate the therapeutic potential of this system in human-induced pluripotent stem cell (hiPSC)-derived neuronal models.

Main Methods:

  • Development of an all-in-one lentiviral vector system using CRISPR-dSaCas9 and a guide RNA (gRNA) targeting SNCA intron 1.
  • Fusion of the CRISPR system with a KRAB/MeCp2 transcription repression domain (TRD) for gene silencing.
  • Utilizing neuronal-type-specific promoters (TH for dopaminergic, ChAT for cholinergic neurons) to drive the therapeutic system.

Main Results:

  • Efficient and specific downregulation of SNCA mRNA and protein in hiPSC-derived neurons from a patient with SNCA triplication.
  • Rescue of disease-related cellular phenotypes, including reduced Ser129-phosphorylated alpha-synuclein, improved neuronal viability, and corrected mitochondrial dysfunction.
  • Successful in vitro proof of concept for a novel, neuron-specific SNCA-targeted epigenome therapy.

Conclusions:

  • A novel neuronal-type-specific epigenome therapy targeting SNCA overexpression has been successfully developed.
  • The system demonstrates significant potential for treating synucleinopathies like PD and DLB.
  • This study provides a strong foundation for further preclinical development and eventual clinical trials.